

Croat Med J. 2014;55:520-9  
doi: 10.3325/cmj.2014.55.520

## Association between total serum cholesterol and depression, aggression, and suicidal ideations in war veterans with posttraumatic stress disorder: a cross-sectional study

**Aim** To investigate the relationship between total serum cholesterol and levels of depression, aggression, and suicidal ideations in war veterans with posttraumatic stress disorder (PTSD) without psychiatric comorbidity.

**Methods** A total of 203 male PTSD outpatients were assessed for the presence of depression, aggression, and suicidality using the 17-item Hamilton Depression Rating Scale (HAM-D<sub>17</sub>), Corrigan Agitated Behavior Scale (CABS), and Scale for Suicide Ideation (SSI), respectively, followed by plasma lipid parameters determination (total cholesterol, high density lipoprotein [HDL]-cholesterol, low density lipoprotein [LDL]-cholesterol, and triglycerides). PTSD severity was assessed using the Clinician-Administered PTSD Scale for DSM-IV, Current and Lifetime Diagnostic Version (CAPS-DX) and the Clinical Global Impressions of Severity Scale (CGI-S), before which Mini-International Neuropsychiatric Interview (MINI) was administered to exclude psychiatric comorbidity and premorbidity.

**Results** After adjustments for PTSD severity, age, body mass index, marital status, educational level, employment status, use of particular antidepressants, and other lipid parameters (LDL- and HDL- cholesterol and triglycerides), higher total cholesterol was significantly associated with lower odds for having higher suicidal ideation (SSI $\geq$ 20) (odds ratio [OR] 0.09; 95% confidence interval [CI] 0.03-0.23), clinically significant aggression (CABS $\geq$ 22) (OR 0.28; 95% CI 0.14-0.59), and at least moderate depressive symptoms (HAM-D<sub>17</sub> $\geq$ 17) (OR 0.20; 95% CI 0.08-0.48). Association of total cholesterol and HAM-D<sub>17</sub> scores was significantly moderated by the severity of PTSD symptoms ( $P < 0.001$ ).

**Conclusion** Our results indicate that higher total serum cholesterol is associated with lower scores on HAM-D<sub>17</sub>, CABS, and SSI in patients with chronic PTSD.

Maja Vilibić<sup>1</sup>, Vlado Jukić<sup>2</sup>,  
Mirna Pandžić-Sakoman<sup>3</sup>,  
Petar Bilić<sup>4</sup>, Milan  
Milošević<sup>5</sup>

<sup>1</sup>Department of Biological Psychiatry and Psychogeriatrics, Vrapče University Psychiatric Hospital, Zagreb, Croatia

<sup>2</sup>Department of Forensic Psychiatry, Vrapče University Psychiatric Hospital, Zagreb, Croatia

<sup>3</sup>Department of Social Psychiatry, Vrapče University Psychiatric Hospital, Zagreb, Croatia

<sup>4</sup>Department for Diagnostic and Intensive Treatment, Vrapče University Psychiatric Hospital, Zagreb, Croatia

<sup>5</sup>Andrija Štampar School of Public Health, Zagreb, Croatia

Received: January 19, 2014

Accepted: October 24, 2014

**Correspondence to:**

Maja Vilibic  
Vrapce University Psychiatric  
Hospital  
Department of Biological Psychiatry  
and Psychogeriatrics  
Bolnicka 32  
10 090 Zagreb, Croatia  
[maja.vilibic@gmail.com](mailto:maja.vilibic@gmail.com)

Posttraumatic stress disorder (PTSD) is one of the few mental disorders with a clearly identifiable cause. It is an anxiety disorder caused by exposure to a traumatic event that presented a threat to the physical integrity of persons themselves or other people in their surroundings (1). Key neurochemical PTSD features include altered catecholamines regulation, alterations in serotonergic system, and alterations in systems of aminoacids, peptides, and opioid neurotransmitters (2).

Associations between serum lipids and various psychiatric disorders and some behavioral aspects (like aggressive behavior) and/or suicidality have been widely explored. Lower total cholesterol levels were predominantly found in patients with major depressive disorder (MDD) (3-9). Significantly higher high-density lipoprotein cholesterol (HDL-cholesterol) levels were found in depressive patients than in controls (7). Some studies found significantly lower HDL-cholesterol levels (10) and a lower HDL-cholesterol/total cholesterol ratio (5) in patients with MDD than in controls.

A negative correlation (11-13) between serum cholesterol level and aggressive behavior was also found, confirming the cholesterol-serotonergic hypothesis of aggression (14,15). Inadequate cholesterol intake could lead to decreased central serotonin activity, which is associated with an increased risk for impulsive-aggressive behavior (14-18). Depression (19-21) and aggression are well-known suicidality risk factors (15,22).

The correlation between hypocholesterolemia, decreased central serotonin activity, increased depressive potential, and increased suicidality risk (23-27) was confirmed, implicating that hypocholesterolemia might be indirectly, ie, through decreased central serotonin activity and increased depression potential (20,25,28), associated with an increased suicidality risk (15,19-24,26,27). In patients with anxiety disorders other than PTSD, like panic disorder (PD), lower HDL-cholesterol and higher very low density lipoprotein cholesterol (VLDL-cholesterol) levels were found to be associated with higher suicide ideations/risk (29). Significantly lower serum total cholesterol and LDL cholesterol levels were found in suicidal patients with PD than in control subjects (30).

Hypercholesterolemia was found to be associated with chronic, war-related PTSD (31-34). In a study from Bosnia and Herzegovina, not only hypercholesterolemia but also increased VLDL- and HDL-cholesterol levels were found in

war veterans with PTSD in comparison with war veterans without psychiatric disorders (35). A Croatian study found no significant differences in the total serum cholesterol level, LDL-, and HDL-cholesterol between war veterans with PTSD, war veterans without PTSD, and healthy volunteers (36). The aim of this study was to investigate the relationship between serum cholesterol and levels of depression, aggression, and suicidal ideations in war veterans with PTSD free of other psychiatric premorbidity and comorbidity.

## PATIENTS AND METHODS

### Patients

This single-center, cross-sectional study included patients consecutively sampled from the pool of veterans involved in outpatient PTSD program at the Department for Biological Psychiatry and Psychogeriatrics and the Department for Diagnostic and Intensive Treatment, University Psychiatric Hospital Vrapče, Zagreb, Croatia. The study was approved by the Ethics Committee of the Vrapče University Psychiatric Hospital. The participants were not reimbursed for their participation in the study and received no benefit in their treatment in comparison with outpatients with PTSD treated in the same hospital but not included in the study. Participants were consecutively recruited from January 2007 till November 2012. Out of 427 examined potential study participants, 10 refused to participate and 214 were not eligible for the study. Out of 203 included study participants, all 203 finished the study.

The study included adult men with chronic, war-related PTSD who met all of the following inclusion criteria: (i) signed an informed consent prior to any study procedure, (ii) male sex, (iii) age between 18 and 65 years, (iv) outpatient status, and (v) confirmed PTSD according to both ICD-10 (37) and DSM-IV (1) criteria. The exclusion criteria were (i) premorbid or comorbid psychiatric disorders (including alcohol and other dependence disorders, eating disorders, or any other psychiatric disorder or condition different from PTSD), (ii) significant somatic comorbidity (particularly those diseases and disorders, like metabolic, with significant influence on cholesterol and other serum lipids metabolism including malnutrition, malabsorption, chronic infections, consumptive disorders, hyper- and hypothyreosis, diabetes mellitus), (iii) BMI over than 20 kg/m<sup>2</sup>, and (iv) taking medicaments with significant influence on serum lipids metabolism (particularly hypolipemics).

### Psychiatric evaluation

All patients met the ICD-10 PTSD criteria, which is the official classification used in Croatian psychiatric practice. PTSD severity was assessed by DSM-IV-based Clinician-Administered PTSD Scale, Current and Lifetime Diagnostic Version (CAPS-DX) (38) and the Clinical Global Impressions of Severity (CGI-S) scale (39), before which Mini-International Neuropsychiatric Interview (MINI) (40) was administered. MINI, a structured diagnostic interview, was used to confirm that each patient met DSM-IV PTSD criteria with the exclusion of psychiatric comorbidity and premorbidity.

After three consecutively administered scales (MINI, CAPS-DX, and CGI-S), the following standardized psychometric instruments/questionnaires were used: Corrigan Agitated Behavior Scale (CABS) (41), 17-item Hamilton Depression Rating Scale (HAM-D<sub>17</sub>) (42), and the Scale for Suicide Ideation (SSI) (43). CABS was used for assessment of the current aggression level (aggressive behaviors), HAM-D<sub>17</sub> for depression potential (subsyndromal depressive states), and SSI for suicidality potential (suicidal ideations). All six scales were applied by experienced psychiatrists, licensed for their administration. The scales were used in their original formats and language, whereas the interview was conducted in Croatian. HAM-D<sub>17</sub> is one of the most frequently used clinician-administered depression assessment scales. It has 17 items; the score of 0-6 points is considered normal, while the score of 7-16 points indicates mild, 17-24 points moderate, and  $\geq 25$  points severe depression. Scores  $\geq 17$  points usually indicate clinically significant levels of depressive symptoms (42). Inter-rater reliability for HAM-D<sub>17</sub> is high, ranging from 0.80 to 0.98 for the total score rating. The test-retest reliability is also high, about 0.81. The validity of the HAM-D<sub>17</sub> ranges from 0.65 to 0.90, with global measures of depression severity (44). In this study, HAM-D<sub>17</sub> reliability calculated as internal consistency (Cronbach's  $\alpha$ ) was 0.66. The Guttman Split-Half Coefficient of reliability was 0.72 and the Spearman-Brown coefficient for unequal length scale half was 0.72.

CABS is an observational, clinician administered, as opposed to self-report, scale. Original validation study showed that trained therapists can use the scale with sufficient reliability and validity when based on therapists' 30-minute observation periods (41). Each of the 14 items is rated on a 4-point rating scale and the total score is calculated by adding up the rating on each of 14 items. Scores of  $\geq 22$  usually indicate a clinically significant result (41). In this study, Cronbach's coefficient of internal CABS scale

consistency was 0.96. The Guttman Split-Half Coefficient of reliability was 0.97 and the Spearman-Brown coefficient for unequal length scale half was 0.97.

The SSI is a 19-item clinician administered scale, widely used to quantify and assess suicidal intention. Each item consists of three alternative statements graded in intensity from 0 to 2. The possible range of scores is 0-38. Inter-rater reliability for SSI is high with correlations ranging from 0.83 (43) to 0.98 (45). The SSI is one of the few suicide assessment instruments to have documented the predictive validity for completed suicide. Psychiatric patients who entered the higher risk category were about seven times more likely to actually commit suicide than those who entered the lower risk category (46). In this study, Cronbach's coefficient of internal SSI scale consistency was 0.94. The Guttman Split-Half Coefficient of reliability was 0.88 and the Spearman-Brown coefficient for unequal length scale half was 0.94. All scale administrators in this study were experienced and licensed in applying the English version of the scales, all in accordance with psychiatric scientific practice in Croatia.

### Medical assessment

General socio-demographic data: age, sex, marital and employment status, and educational level were collected by means of a clinical interview. Data on pharmacotherapy influencing serum lipids metabolism and psychopharmaceuticals taking, were collected from patients' medical records. Data on significant somatic comorbidities were collected through physical examination and somatic anamnesis. Body weight (in kilograms, kg) and body height (in meters, m) were measured and BMI was calculated according to the following formula:  $BMI = \text{weight in kg} / \text{height in squared meters}$ .

### Biochemical analysis

Biochemical analyses were performed at the Laboratory of the Vrapče University Psychiatric Hospital. Lipid levels were determined using commercial tests: cholesterol (enzymatic colorimetric method), HDL-cholesterol (homogeneous enzymatic colorimetric assay), LDL-cholesterol (homogeneous enzymatic colorimetric assay), and triglycerides (enzymatic colorimetric method with glycerol phosphate oxidase and 4-aminophenazone (GPO/PAP) (Roche Diagnostics, Mannheim, Germany). Concentrations were expressed in mmol/L. At two consecutive time points (separated by less than 10 but more than two days), 10 mL of

blood was drawn from the cubital vein and levels of plasma lipids were determined. Blood samples were drawn between 8:00 and 9:30 AM, after 12 hours of overnight fasting. They were collected using a standardized process, all in accordance with the Helsinki Declaration (47). According to the mean total cholesterol value ([value from the first sample + value from the second sample]/2), each patient was classified into one of three groups: normal group (cholesterol 3.1-5.1 mmol/L), borderline-high/high-normal group (cholesterol 5.2-6.2 mmol/L), and high cholesterol group (cholesterol >6.2 mmol/L), all in accordance with the current international guidelines (48).

### Outcomes

Three outcomes were HAM-D<sub>17</sub>, CABS, and SSI scales results dichotomized as to indicate at least moderate depressive symptoms (HAM-D<sub>17</sub> ≥ 17), clinically significant aggression (CABS ≥ 22), and higher – the upper quartile – suicidal ideation (SSI ≥ 20).

### Statistical analysis

The level of statistical significance was set at  $P < 0.05$  and confidence intervals at 95%. In all instances, two-tailed tests were used. Principal component analysis with extraction criterion eigenvalues >1 and Vairmax rotation with Kaiser normalization was done in order to explore the possibility of reducing dimensionality of psychometric outcomes. A univariate analysis of the relationship between lipid parameters, PTSD severity, patient's living conditions, and therapy was performed by binary logistic regression. A multivariate analysis of relationship between total cholesterol and three psychometric scales scores after adjustment for PTSD severity, age, BMI, marital status, educational level, employment status, the use of particular antidepressants, and other lipid parameters (LDL- and HDL-cholesterol and triglycerides) was done using hierarchical binary logistic regression. The moderating effect of PTSD severity on the association of total cholesterol and three psychometric scales scores was analyzed by Process (49). The CAPS value defining the region of statistically significant association of total cholesterol and three psychometric scales was assessed by Johnson-Neyman technique as implemented in the Process. Data analysis was carried out by R (50).

### RESULTS

Out of the 427 potential study participants, 203 met all inclusion criteria and had none of the exclusion criteria (10

**TABLE 1.** Baseline characteristics of 203 male patients with posttraumatic stress disorder (PTSD)\*

Characteristic	
Age (years) <sup>†</sup>	47.0 (43.0-54.0)
PTSD symptoms severity score:	
CAPS-DX total <sup>†</sup>	70.0 (65.0-76.0)
CGI-S	
moderately ill, n (%)	111 (54.7)
markedly ill, n (%)	92 (45.3)
Living conditions:	
Marital status	
married, n (%)	143 (70.4)
divorced, n (%)	41 (20.2)
single, n (%)	19 (9.4)
Living alone	
yes, n (%)	60 (29.6)
no, n (%)	143 (70.4)
Educational level	
elementary school, n (%)	70 (34.5)
high school, n (%)	122 (60.1)
>high school, n (%)	11 (5.4)
Employment status	
full-time, n (%)	37 (18.2)
part-time, n (%)	12 (5.9)
unemployed but able to work, n (%)	40 (19.7)
sick-leave and unemployed unable to work, n (%)	20 (9.9)
retired, n (%)	94 (46.3)
Lipid parameters (mmol/L): <sup>†</sup>	
total cholesterol	5.7 (5.0-6.0)
LDL-C	3.4 (2.9-3.8)
HDL-C	1.0 (1.0-1.4)
triglycerides	2.3 (1.5-2.9)
BMI <sup>†</sup>	26.1 (25.2-27.6)
Therapy:	
Antidepressants	
SSRI, n (%)	140 (69.0)
SNRI, n (%)	34 (16.7)
NaSSA, n (%)	29 (14.3)
Anxiolytics	
diazepam, n (%)	74 (36.5)
alprazolam, n (%)	58 (28.6)
clonazepam, n (%)	30 (14.8)
oxazepam, n (%)	25 (12.3)
lorazepam, n (%)	16 (7.9)
Hypnotics	
zolpidem, n (%)	159 (78.3)
nitrazepam, n (%)	44 (21.7)
Psychometric scales: <sup>†</sup>	
SSI	13.0 (7.0-19.0)
CABS	19.0 (17.0-32.0)
HAM-D <sub>17</sub>	18.0 (16.0-22.0)

\*Abbreviations: CAPS – Clinician-Administered PTSD Scale for DSM-IV, Current and Lifetime Diagnostic Version (38); a higher score reflects higher PTSD severity; CGI-S – Clinical Global Impressions of Severity Scale (39); a higher score reflects higher PTSD severity; LDL-C – low density lipoprotein cholesterol; HDL-C – high density lipoprotein cholesterol; BMI – body mass index; SSRI – selective serotonin reuptake inhibitors; SNRI – serotonin norepinephrine reuptake inhibitors; NaSSA – noradrenergic and specific serotonergic antidepressants; SSI – Scale for Suicide Ideation (43); a higher score reflects higher suicidality potential; CABS – Corrigan Agitated Behavior Scale (41); a higher score reflects higher aggressive potential; HAM-D<sub>17</sub> – Hamilton Depression Rating Scale (42); a higher score reflects higher depressive potential.

†Median (interquartile range).

refused to participate and 214 were not eligible for the study). Their median (interquartile range) age was 47.0 years (43.0-54.0) and all of them were either moderately or markedly ill as measured by CGI-S (Table 1). All patients were treated with a combination of antidepressant, anxiolytic, and hypnotic treatment prescribed in standard medium dosages. By principal component analysis, 11 principal components were extracted, explaining 75% of items variance. However, the first three components (corresponding to HAM-D<sub>17</sub>, CABS, and SSI scales) explained 20%, 18%, and 9% of original items, respectively. All other components individually explained less than 4% of total variance. Varimax rotation with Kaiser normalization produced the structure matrix with very clear distinction between original HAM-D, SSI, and CABS items. Therefore, we concluded that our three dependent variables were well discriminated, and that treating CABS, SSI, and HAM-D as separate outcomes was the most appropriate approach.

Univariate binary logistic regression revealed that higher total cholesterol and LDL-cholesterol were significantly associated with lower odds for having higher suicidal ideation (SSI $\geq$ 20), clinically significant aggression (CABS $\geq$ 22), and at least moderate depressive symptoms (HAM-D<sub>17</sub> $\geq$ 17) (Table 2). Higher triglycerides were associated with lower odds for higher suicidal ideation and aggression. After the adjustments for PTSD severity, age, BMI, marital status, educational level, employment status, use of particular antidepressants, and other lipid parameters (LDL and HDL cholesterol and triglycerides), higher total cholesterol was significantly associated with lower odds for having the higher suicidal ideation (SSI $\geq$ 20), clinically significant aggression (CABS $\geq$ 22), and at least moderate depressive symptoms (HAM-D<sub>17</sub> $\geq$ 17) (Table 3). When the total cholesterol was removed from the equation adjusted for patients' clinical characteristics, living conditions, and therapy, LDL-cholesterol was significantly negatively associated with lower odds for our three outcomes; HDL-cholesterol and triglycerides were significantly associated

with suicidal ideation but not with aggression or depressive symptoms.

We found no significant moderating effect of PTSD severity on the association of total cholesterol and high SSI scale score. Association of total cholesterol and HAM-D<sub>17</sub> score was significantly moderated by PTSD severity. At the 10th percentile of the CAPS scale result, association of total cholesterol and HAM-D<sub>17</sub> score was not significant (odds ratio [OR] 0.46; 95% confidence interval [CI] 0.21-1.01;  $P=0.053$ ). At the 90th percentile of the CAPS scale result, association of total cholesterol and HAM-D<sub>17</sub> score was significant (OR 0.15; 95% CI 0.07-0.34;  $P<0.001$ ). The Johnson-Neyman technique revealed that association of total cholesterol and HAM-D<sub>17</sub> score was significant at CAPS value of 59.1, which corresponds to -1.5 CAPS standard deviations. Although the overall moderating effect of PTSD severity on the association of total cholesterol and CABS was not significant ( $P=0.395$ ), the Johnson-Neyman technique revealed that association of total cholesterol and the CABS score was significant if the CAPS score was lower than 83.9, which corresponds to 1.5 CAPS standard deviation.

## DISCUSSION

The present study found an independent association between higher serum total cholesterol and lower odds for having higher suicidal ideation (SSI $\geq$ 20), clinically significant aggression (CABS $\geq$ 22), and at least moderate depressive symptoms (HAM-D<sub>17</sub> $\geq$ 17) in male war veterans with PTSD without other psychiatric comorbidities. The association between total cholesterol and HAM-D<sub>17</sub> scores and between total cholesterol and CABS scores was different in different PTSD severity groups. Consistently, previous studies reported higher prevalence of depressive symptoms in middle-aged men with lower cholesterol levels ( $\leq$ 4.5 mmol/L) than in men with cholesterol levels between 6 and 7 mmol/L (51). An American study failed to find a sig-

**TABLE 2.** Univariate association of lipid parameters with elevated SSI, CABS, HAM-D<sub>17</sub> scales results (n = 203)\*

Lipid parameters (mmol/L):	Suicidal ideation (SSI $\geq$ 20)			Aggression (CABS $\geq$ 22)			Depression (HAM-D <sub>17</sub> $\geq$ 17)		
	OR	(95% CI)	P	OR	(95% CI)	P	OR	(95% CI)	P
total cholesterol	0.10	(0.05-0.2)	<0.001	0.33	(0.21-0.53)	<0.001	0.26	(0.16-0.42)	<0.001
LDL-C	0.27	(0.14-0.51)	<0.001	0.41	(0.24-0.68)	0.001	0.45	(0.29-0.71)	0.001
HDL-C	0.90	(0.45-1.78)	0.755	1.28	(0.72-2.29)	0.399	0.89	(0.51-1.56)	0.684
triglycerides	0.63	(0.44-0.90)	0.010	0.71	(0.53-0.95)	0.023	0.83	(0.64-1.06)	0.139

\*Abbreviations: OR – odds ratio, univariate binary logistic regression; 95% CI – 95% confidence interval; LDL-C – low density lipoprotein cholesterol; HDL-C – high density lipoprotein cholesterol; SSI – Scale for Suicide Ideation (43); a higher score reflects higher suicidality potential; CABS – Corrigan Agitated Behavior Scale (41); a higher score reflects higher aggressive potential; HAM-D<sub>17</sub> – Hamilton Depression Rating Scale (42); a higher score reflects higher depressive potential.

nificant difference in the severity of depressive symptoms between the group of middle-aged adults with low (<3.9 mmol/L) and the group with total cholesterol ≥3.9 mmol/L (52). Various studies have found a negative association between total serum cholesterol and MDD, mostly associating lower levels of serum cholesterol with MDD (3-9,53,54). Higher serum cholesterol levels could be indirectly associated with lower levels of depression (depressive symptoms at a subsyndromal level) due to higher central serotonin activity than that expected in patients with lower serum cholesterol levels (25). Hypocholesterolemic status could be accompanied by more negative affective states at the clinical level (depressive symptoms more manifested, even in a full syndromal form – MDD) (20,25,28,51). However, in

our PTSD population, neither low cholesterol levels nor MDD comorbidity were found.

In this study, a negative association between total cholesterol and CABS score was found. Literature data linked lower total cholesterol levels to higher rates of aggressive and violent behavior (11-13,55,56). In our study, higher serum total cholesterol levels were accompanied by less manifested agitation and aggressive behavioral patterns. Despite the lack of clinically significant manifestations of aggressive behaviors, patients with normal serum cholesterol levels in our sample manifested more aggressive behavioral patterns than those with borderline-high and high serum cholesterol levels.

**TABLE 3.** Multivariate association of lipid parameters after adjustment for possible confounders with elevated SSI, CABS, HAM-D<sub>17</sub> scales results (n = 203)\*

	Suicidal ideation (SSI≥20)			Aggression (CABS≥22)			Depression (HAM-D17≥17)		
	OR	(95% CI)	P	OR	(95% CI)	P	OR	(95% CI)	P
<b>Lipid parameters* (mmol/L):</b>									
total cholesterol	0.09	(0.03-0.23)	<0.001	0.28	(0.14-0.59)	0.001	0.20	(0.08-0.48)	<0.001
LDL-C	1.27	(0.48-3.38)	0.629	1.05	(0.51-2.15)	0.894	1.47	(0.61-3.52)	0.391
HDL-C	0.97	(0.29-3.21)	0.956	1.73	(0.74-4.07)	0.209	1.15	(0.48-2.75)	0.751
triglycerides	0.90	(0.56-1.45)	0.669	0.90	(0.61-1.33)	0.604	0.99	(0.67-1.47)	0.970
<b>Confounders:</b>									
Age (years)	1.00	(0.94-1.06)	0.886	0.98	(0.93-1.03)	0.484	1.01	(0.96-1.07)	0.618
BMI	0.97	(0.82-1.16)	0.756	1.02	(0.88-1.19)	0.768	1.04	(0.88-1.22)	0.665
CAPS	0.98	(0.93-1.03)	0.356	0.98	(0.94-1.02)	0.357	0.98	(0.94-1.02)	0.363
<b>Marital status</b>									
married	1			1			1		
divorced	1.04	(0.35-3.12)	0.945	1.47	(0.62-3.51)	0.381	2.75	(1.12-6.78)	0.028
single	0.96	(0.17-5.49)	0.960	1.17	(0.32-4.32)	0.811	0.69	(0.20-2.35)	0.548
<b>Educational level</b>									
elementary school	1			1			1		
high school	0.91	(0.34-2.43)	0.852	0.81	(0.37-1.77)	0.598	1.21	(0.58-2.51)	0.619
>high school	4.45	(0.73-27.30)	0.104	0.58	(0.11-3.02)	0.515	3.80	(0.60-23.9)	0.156
<b>Employment status</b>									
full-time	1			1			1		
part-time	0.69	(0.06-8.11)	0.767	4.02	(0.71-22.91)	0.117	0.63	(0.12-3.29)	0.580
unemployed but able to work	1.48	(0.34-6.43)	0.605	0.63	(0.16-2.47)	0.506	0.83	(0.27-2.50)	0.733
sick-leave and unemployed unable to work	2.30	(0.45-11.69)	0.315	3.18	(0.78-12.91)	0.106	3.99	(0.96-16.7)	0.058
retired	1.13	(0.31-4.06)	0.853	3.22	(1.11-9.32)	0.031	0.99	(0.39-2.50)	0.977
<b>Antidepressants</b>									
SSRI	1.24	(0.36-4.24)	0.737	0.28	(0.11-0.75)	0.011	0.24	(0.08-0.76)	0.016
SNRI	1.95	(0.43-8.85)	0.386	0.59	(0.18-1.91)	0.379	0.32	(0.09-1.18)	0.087
NaSSA	1			1			1		

\*Abbreviations: OR – odds ratio, multivariate binary logistic regression; 95% CI – 95% confidence interval; P – level of statistical significance; CAPS – Clinician-Administered PTSD Scale for DSM-IV, Current and Lifetime Diagnostic Version (38); a higher score reflects higher PTSD severity; LDL-C – low density lipoprotein cholesterol; HDL-C – high density lipoprotein cholesterol; SSRI – selective serotonin reuptake inhibitors; SNRI – serotonin norepinephrine reuptake inhibitors; NaSSA – noradrenergic and specific serotonergic antidepressants; SSI – Scale for Suicide Ideation (43); a higher score reflects higher suicidality potential; CABS – Corrigan Agitated Behavior Scale (41); a higher score reflects higher aggressive potential; HAM-D<sub>17</sub> – Hamilton Depression Rating Scale (42); a higher score reflects higher depressive potential.

Similarly to our results, other studies (23,24,26,27) also reported an association between low total cholesterol levels and suicidality, while one recent study found that only very low and very high cholesterol levels could be valid and reliable predictors of suicidal ideations incidence in elderly people (57).

In PTSD patients with high (>6.2 mmol/L) cholesterol levels and those with cholesterol levels within the upper range of borderline-high cholesterol category (cholesterol between 5.5-6.2 mmol/L), suicidal ideations were less pronounced than in patients with cholesterol below this value (5.5 mmol/L was the cut-off) but with each subsequent lowering of the serum cholesterol levels below the 5.5 mmol/L level, the SSI scores significantly increased. Our patients with normal serum total cholesterol levels had significantly more pronounced suicidal tendencies than those with borderline-high and high cholesterol levels. According to the trend described above, an even stronger association between low serum total cholesterol levels and high SSI scores could be expected in rare cases of low serum cholesterol. Serum cholesterol levels could represent cardiovascular risk factors, but it seems that they might have a protective effect against suicidal ideation in patients with PTSD. With a lowering of serum cholesterol values from high to normal levels, this protective effect weakens and suicidal tendencies increase, while with further lowering of serum cholesterol levels to hypocholesterolemic range, the increase becomes even more obvious.

Since some depressive symptoms may be attributed to PTSD clinical presentation, if the severity of PTSD symptoms reaches a critical level, their impact on the association between total cholesterol and depressive symptoms could become clinically significant. Previous studies focused on depression (MDD) comorbidity in combat-related PTSD suggest that PTSD may be a causal risk factor for subsequent depression (56). Depression comorbidity in PTSD has been associated with more severe and chronic symptomatology (58,59). Despite the fact that none of our patients had comorbid MDD, it seems that in patients with severe PTSD symptomatology (all of our patients were either markedly or moderately ill), PTSD itself could present a causal risk factor for subsequent depression (in our patients at subsyndromal level, depressive symptoms were present but not MDD comorbidity), partially mediated via serum cholesterol.

A limitation of our study was the cross-sectional design – we had a single fasting lipid measurement so the

reliability of our independent variables may be insufficient. Also, without a control group, we might not have taken into account some confounding effects.

In conclusion, our results indicate a negative association between total cholesterol and higher suicidal ideation, clinically significant aggression, and at least moderate depressive symptoms. As a future research topic, we propose the analysis of a possible moderating effect of PTSD severity on the association of total cholesterol and the symptoms of depression. Monitoring of lipid level changes in PTSD patients could improve the therapeutic outcomes.

**Funding** None.

**Ethical approval** received from the Ethics Committee of the University Psychiatric Hospital Vrapče.

**Declaration of authorship** MV contributed to study design, data collection, analysis, and interpretation, and manuscript writing. VJ contributed to study design, data analysis and interpretation, and critical revision of the manuscript. MPS contributed to study design, acquisition of data, and manuscript writing. PB contributed to study design, acquisition of data, and revision of the manuscript. MM contributed to study design, analysis and interpretation of data, and manuscript writing.

**Competing interests** All authors have completed the Unified Competing Interest form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

## References

- 1 American Psychiatric Association. Diagnostic statistical manual of mental disorders. Temporary revised 4th ed. Washington (DC): American Psychiatric Association Press; 2000.
- 2 Muck-Šeler D, Mustapić M, Nedić G, Babić A, Mimica N, Kozarić-Kovačić D, et al. Genetic and biochemical markers of serotonergic and catecholaminergic systems in neuropsychiatric disorder. In: Urbano KV, ed. Advances in genetics research. Volume 3. New York: Nova Science Publishers, Inc.; 2010, p. 1-67.
- 3 De Berardis D, Serroni N, Campanella D, Carano A, Gambi F, Valchera A, et al. Alexithymia and its relationships with C-reactive protein and serum lipid levels among drug naïve adult outpatients with major depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:1982-6. [Medline:18940224](https://pubmed.ncbi.nlm.nih.gov/18940224/) [doi:10.1016/j.pnpbp.2008.09.022](https://doi.org/10.1016/j.pnpbp.2008.09.022)
- 4 Jakovljević M, Reiner Z, Milčić D. Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look and old data. *Psychiatr Danub*. 2007;19:270-81. [Medline:18000478](https://pubmed.ncbi.nlm.nih.gov/18000478/)
- 5 Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. *Acta Psychiatr Scand*. 1997;95:212-21. [Medline:9111854](https://pubmed.ncbi.nlm.nih.gov/9111854/) [doi:10.1111/](https://doi.org/10.1111/)

- j.1600-0447.1997.tb09622.x
- 6 Martínez-Carpio PA, Barba J, Bedoya-Del Campillo A. Relation between cholesterol levels and neuropsychiatric disorders. *Rev Neurol*. 2009;48:261-4. [Medline:19263395](#)
  - 7 Olusi SO, Fido AA. Serum lipid concentrations in patients with major depressive disorder. *Biol Psychiatry*. 1996;40:1128-31. [Medline:8931915](#) [doi:10.1016/S0006-3223\(95\)00599-4](#)
  - 8 Partonen T, Haukka J, Virtamo J, Taylor PR, Lönnqvist J. Association of low serum total cholesterol with major depression and suicide. *Br J Psychiatry*. 1999;175:259-62. [Medline:10645328](#) [doi:10.1192/bjp.175.3.259](#)
  - 9 You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. *Expert Opin Pharmacother*. 2013;14:1467-76. [Medline:23767773](#) [doi:10.1517/1465666.2013.803067](#)
  - 10 Lehto SM, Niskanen L, Tolmunen T, Hintikka J, Viinamäki H, Heiskanen T, et al. Low serum HDL-cholesterol levels are associated with long symptom duration in patients with major depressive disorder. *Psychiatry Clin Neurosci*. 2010;64:279-83. [Medline:20374538](#) [doi:10.1111/j.1440-1819.2010.02079.x](#)
  - 11 Golomb BA. Cholesterol and violence: is there a connection? *Ann Intern Med*. 1998;128:478-87. [Medline:9499332](#) [doi:10.7326/0003-4819-128-6-199803150-00009](#)
  - 12 Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime. *J Psychiatr Res*. 2000;34:301-9. [Medline:11104842](#) [doi:10.1016/S0022-3956\(00\)00024-8](#)
  - 13 Virkkunen M, Penttinen H. Serum cholesterol in aggressive conduct disorder: a preliminary study. *Biol Psychiatry*. 1984;19:435-9. [Medline:6722234](#)
  - 14 Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and cholesterol values in violent and non-violent suicide attempters. *Psychiatry Res*. 2008;158:87-91. [Medline:18155776](#) [doi:10.1016/j.psychres.2003.05.002](#)
  - 15 Ryding E, Lindström M, Träskman-Bendz L. The role of dopamine and serotonin in suicidal behaviour and aggression. *Prog Brain Res*. 2008;172:307-15. [Medline:18772039](#) [doi:10.1016/S0079-6123\(08\)00915-1](#)
  - 16 Coccaro EF, Lee R, Kavoussi RJ. Aggression, suicidality and intermittent explosive disorder: serotonergic correlates in personality disorder and healthy control subjects. *Neuropsychopharmacology*. 2010;35:435-44. [Medline:19776731](#) [doi:10.1038/npp.2009.148](#)
  - 17 Marcinko D, Martinac M, Karlović D, Filipčić I, Loncar C, Pivac N, et al. Are there differences in serum cholesterol and cortisol concentrations between violent and non-violent schizophrenic male suicide attempters? *Coll Antropol*. 2005;29:153-7. [Medline:16117315](#)
  - 18 van Heeringen K. The neurobiology of suicide and suicidality. *Can J Psychiatry*. 2003;48:292-300. [Medline:12866334](#)
  - 19 Degmečić D, Filaković P. Depression and suicidality in the adolescents in Osijek, Croatia. *Coll Antropol*. 2008;32:143-5. [Medline:18496908](#)
  - 20 Gonda X, Fountoulakis KN, Kaprinis G, Rihmer Z. Prediction and prevention of suicide in patients with unipolar depression and anxiety. *Ann Gen Psychiatry*. 2007;6:23. [Medline:17803824](#) [doi:10.1186/1744-859X-6-23](#)
  - 21 Kim YK, Myint AM. Clinical application of low serum cholesterol as an indicator for suicide risk in major depression. *J Affect Disord*. 2004;81:161-6. [Medline:15306143](#) [doi:10.1016/S0165-0327\(03\)00166-6](#)
  - 22 McGirr A, Turecki G. The relationship of impulsive aggressiveness to suicidality and other depression-linked behaviors. *Curr Psychiatry Rep*. 2007;9:460-6. [Medline:18221625](#) [doi:10.1007/s11920-007-0062-2](#)
  - 23 Colin A, Reggers J, Castronovo V, Ansseau M. Lipids, depression and suicide. *Encephale*. 2003;29:49-58. [Medline:12640327](#)
  - 24 Coryell W, Schlessler M. Combined biological tests for suicide prediction. *Psychiatry Res*. 2007;150:187-91. [Medline:17289156](#) [doi:10.1016/j.psychres.2006.01.021](#)
  - 25 Mössner R, Mikova O, Koutsilieri E, Saoud M, Ehliis AC, Müller N, et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. *World J Biol Psychiatry*. 2007;8:141-74. [Medline:17654407](#) [doi:10.1080/15622970701263303](#)
  - 26 Papassotiropoulos A, Hawellek B, Frahnert C, Rao GS, Rao ML. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol. *Pharmacopsychiatry*. 1999;32:1-4. [Medline:10071176](#) [doi:10.1055/s-2007-979181](#)
  - 27 Ruljancic N, Mihanovic M, Cepelak I. Thrombocyte serotonin and serum cholesterol concentration in suicidal and non-suicidal depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:1261-7. [Medline:21338651](#) [doi:10.1016/j.pnpbp.2011.02.007](#)
  - 28 Meltzer H. Serotonergic dysfunction in depression. *Br J Psychiatry Suppl*. 1989;8:25-31. [Medline:2692637](#)
  - 29 De Berardis D, Campanella D, Serroni N, Moschetta FS, Di Emidio F, Conti C, et al. Alexithymia, suicide risk and serum lipid levels among adult outpatients with panic disorder. *Compr Psychiatry*. 2013;54:517-22. [Medline:23332553](#) [doi:10.1016/j.comppsy.2012.12.013](#)
  - 30 Ozer OA, Kutaniş R, Agargun MY, Be Şiroğlu L, Bal AC, Selvi Y, et al. Serum lipid levels, suicidality, and panic disorder. *Compr Psychiatry*. 2004;45:95-8. [Medline:14999659](#) [doi:10.1016/j.comppsy.2003.12.004](#)
  - 31 Filaković P, Barkić J, Kadoić D, Crncević-Orlić Z, Grgurić-Radanović Lj, Karner I, et al. Biologic parameters of posttraumatic stress disorder. *Psychiatr Danub*. 1997;9:207-11.
  - 32 Kagan BL, Leskin G, Haas B, Wilkins J, Foy D. Elevated lipid levels in Vietnam veterans with chronic posttraumatic stress disorder. *Biol Psychiatry*. 1999;45:374-7. [Medline:10023518](#) [doi:10.1016/S0006-](#)



- 3223(98)00059-6
- 33 Karlović D, Buljan D, Martinac M, Marcinko D. Serum lipid concentrations in Croatian veterans with post-traumatic stress disorder, post-traumatic stress disorder comorbid with major depressive disorder, or major depressive disorder. *J Korean Med Sci.* 2004;19:431-6. [Medline:15201512](#) [doi:10.3346/jkms.2004.19.3.431](#)
  - 34 Solter V, Thaller V, Karlović D, Crnković D. Elevated serum lipids in veterans with combat-related chronic posttraumatic stress disorder. *Croat Med J.* 2002;43:685-9. [Medline:12476477](#)
  - 35 Dzubur Kulenović A, Kucukalić A, Malec D. Changes in plasma lipid concentrations and risk of coronary artery disease in army veterans suffering from chronic posttraumatic stress disorder. *Croat Med J.* 2008;49:506-14. [Medline:18716998](#) [doi:10.3325/cmj.2008.4.506](#)
  - 36 Jendricko T, Vidović A, Grubisić-Ilić M, Romić Z, Kovacic Z, Kozarić-Kovacic D. Homocystein and serum lipids concentrations in male veterans with posttraumatic stress disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009;33:134-40. [Medline:19038303](#) [doi:10.1016/j.pnpbp.2008.11.002](#)
  - 37 World Health Organisation. ICD-10, International Statistical Classification of Diseases and Health Related Problems, 10th Revision, ed 1. Geneva: World Health Organisation; 1992.
  - 38 Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Charney DS, Keane TM. Clinician-Administered PTSD Scale for DSM-IV. Current and Lifetime Diagnostic Version (CAPS-DX). Rev. Ed. Boston and West Haven: National Center for Posttraumatic Stress Disorder; 1996. p. 1-18.
  - 39 Guy W. Early clinical drug evaluation, psychopharmacology research branch. In: ECDEU assessment manual for psychopharmacology, revised 1976. Rockville, MD: National Institute of Mental Health; 1976. p. 217-22.
  - 40 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry.* 1998;59:22-33. [Medline:9881538](#)
  - 41 Corrigan JD. Development of a scale for assessment of agitation following traumatic brain injury. *J Clin Exp Neuropsychol.* 1989;11:261-77. [Medline:2925835](#) [doi:10.1080/01688638908400888](#)
  - 42 Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry.* 1960;23:56-62. [Medline:14399272](#) [doi:10.1136/jnnp.23.1.56](#)
  - 43 Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. *J Consult Clin Psychol.* 1979;47:343-52. [Medline:469082](#) [doi:10.1037/0022-006X.47.2.343](#)
  - 44 Cusin C, Huaiyu Y, Yeung A, Fava M. Rating scales for depression. In: BaerL, Blais MA, eds. *Handbook of clinical rating scales and assessment in psychiatry and mental health, current clinical psychiatry.* Ney York, NY: Humanna Press; 2009, p. 9.
  - 45 Beck AT, Brown GK, Steer RA. Psychometric characteristics of the scale for suicide ideation with psychiatric outpatients. *Behav Res Ther.* 1997;35:1039-46. [Medline:9431735](#) [doi:10.1016/S0005-7967\(97\)00073-9](#)
  - 46 Brown GK, Beck AT, Steer RA, Grisham JR. Risk factors for suicide in psychiatric outpatients: A 20-year prospective study. *J Consult Clin Psychol.* 2000;68:371-7. [Medline:10883553](#) [doi:10.1037/0022-006X.68.3.371](#)
  - 47 Declaration of Helsinki. Ferney-Voltaire: World Medical Association; 1964.
  - 48 Roth GA, Fihn SD, Mokdad AH, Wichai A, Hasegawa T, Lim SS. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. *Bull World Health Organ.* 2011;89:92-101. [Medline:21346920](#) [doi:10.2471/BLT.10.079947](#)
  - 49 "Process", release 2.12, Andrew F. Hayes, The Ohio State University, 2014.
  - 50 Development Core Team. (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: <http://www.R-project.org>. Accessed: October 23, 2014.
  - 51 Steegmans PH, Hoes AW, Bak AA, van der Does E, Grobbee DE. Higher prevalence of depressive symptoms in middle-aged men with low serum cholesterol levels. *Psychosom Med.* 2000;62:205-11. [Medline:10772398](#) [doi:10.1097/00006842-200003000-00009](#)
  - 52 Sahebzamani FM, D'Aoust RF, Friedrich D, Aiyer AN, Reis SE, Kip KE. Relationship among low cholesterol levels, depressive symptoms, aggression, hostility, and cynicism. *J Clin Lipidol.* 2013;7:208-16. [Medline:23725920](#) [doi:10.1016/j.jacl.2013.01.004](#)
  - 53 Kale AB, Kale SB, Chalak SS, S RT, Bang G, Agrawal M, et al. Lipid parameter – significance in patients with endogenous depression. *J Clin Diagn Res.* 2014;8:17-9. [Medline:24596713](#)
  - 54 Patra BN, Khandelwal SK, Chadda RK, Ramakrishnan L. A controlled study of serum lipid profiles in Indian patients with depressive episode. *Indian J Psychol Med.* 2014;36:129-33. [Medline:24860211](#) [doi:10.4103/0253-7176.130968](#)
  - 55 Liu J, Wuerker A. Biosocial bases of aggressive and violent behaviour-implications for nursing studies. *Int J Nurs Stud.* 2005;42:229-41. [Medline:15680620](#) [doi:10.1016/j.ijnurstu.2004.06.007](#)
  - 56 Wallner B, Machatschke IH. The evolution of violence in men: the function of central cholesterol and serotonin. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009;33:391-7. [Medline:19223008](#) [doi:10.1016/j.pnpbp.2009.02.006](#)
  - 57 Kim JM, Stewart R, Kang HJ, Jeong BO, Kim SY, Bae KY, et al. Logitudinal association between serum cholesterol levels and suicidal ideation in an older Korean population. *J Affect Disord.* 2014;152-154:517-21. [Medline:24007784](#) [doi:10.1016/j.jad.2013.08.008](#)

- 58 Stander VA, Thomsen CJ, Highfill-McRoy RM. Etiology of depression comorbidity in combat-related PTSD: a review of the literature. *Clin Psychol Rev.* 2014;34:87-98. [Medline:24486520](#) [doi:10.1016/j.cpr.2013.12.002](#)
- 59 Müller M, Vandeleur C, Rodgers S, Rössler W, Castelao E, Preisig M, et al. Factors associated with comorbidity patterns in full and partial PTSD: findings from the PsyCoLaus study. *Compr Psychiatry.* 2014;55:837-48. [Medline:24560408](#) [doi:10.1016/j.comppsy.2014.01.009](#)